Deep Dive: Oncology and ASCO 2019

Although we all wish that cancer as a disease area would disappear, we can at least be encouraged that oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference. You can read our exclusive analysis of the conference in this issue, featuring interviews with three experts from Kantar, to find out more.

But with every new oncology development comes a slew of new challenges. In this issue we look at how companies might overcome such issues in the future – experts from ICON discuss the future of Adoptive Cellular Transfer, we hear from Cytel about how clinical trials need to adapt to become more successful, and thought leaders from Research Partnership look at the promise and pitfalls of molecular testing in oncology. We also speak to Pharmerit about revealing the true value of new cancer drugs to payers.

Elsewhere in the issue, we speak to Astellas US president Percival Barretto-Ko about pricing and improving the patient experience, Tag tell us how they’re driving smarter thinking about pharma marketing, and we hear from Impetus Digital’s Natalie Yeadon how digital can be used to get the patient voice into pharma.

I hope you enjoy the issue.

Kind regards,
George

George Underwood – Editor, Deep Dive: Oncology and ASCO 2019